Become a member Register now
Coming soon: xMas 
Special
Special
Special
|
Xlife Sciences AG / Key word(s): Half Year Results/Interim Report Zurich, 19th of September 2024: Xlife Sciences AG (SIX: XLS) today published its 2024 Half-Year Report and announced significant progress in its business development. Despite a challenging market environment, the company was able to further expand its innovative strength and advance new partnerships and developments within its diversified portfolio. The full 2024 Half-Year Report of Xlife Sciences AG is available for download as a PDF document in the «Financial Reports» section at https://www.xlifesciences.ch/en/news-and-key-figures. Operational Highlights in the First Half of 2024 Xlife Sciences AG’s diversified portfolio includes 25 project companies, which achieved important progress during the reporting period. The following highlights are exemplary:
Additionally, significant synergies between portfolio companies were leveraged to promote technological innovations and open up new market segments. Please find more information on this in the letter to our shareholders inside the Half-Year Report. Financial Figures In the first half of 2024, Xlife Sciences generated revenue of CHF 349.818.- (previous year: CHF 347.979.-). Earnings per share amounted to CHF 0.08.- (previous year: CHF -1.10.-). The balance sheet total increased to CHF 509.9 million (previous year: CHF 477.9 million), and equity reached CHF 367.0 million (previous year: CHF 332.6 million). Strategic Partnerships and Internationalization Another focus in the first half of 2024 was the internationalization of the business, particularly through expanded cooperation in Abu Dhabi with partners such as Thermo Fisher Scientific and Masdar City. These partnerships strengthen Xlife Sciences' position as a leading player in life sciences and clinical research on a global scale. Outlook for the Second Half of 2024 Xlife Sciences looks optimistically to the second half of the year and plans further strategic milestones. Two-thirds of the portfolio have reached the «Proof of Concept» status, providing a solid foundation for future growth. Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «Despite a challenging market environment, we were able to achieve significant progress in the first half of 2024. Our innovative projects and strategic partnerships are creating sustainable value for our shareholders. We are well-positioned to achieve further growth and long-term value enhancement.» Financial calendar
Contact Xlife Sciences AG, End of Inside Information |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1991039 |
| End of Announcement | EQS News Service |
|
|
1991039 19-Sep-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
